Fort Sheridan Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-55,177	Closed	-$92.1K	–	291
2025 Q4	$92.1K	Hold	55,177	–	–	0.01%	266
2025 Q3	$93.2K	Hold	55,177	–	–	0.01%	267
2025 Q2	$50.1K	Hold	55,177	–	–	0.01%	251
2025 Q1	$24.9K	Hold	55,177	–	–	﹤0.01%	247
2024 Q4	$27.7K	Buy	55,177 +23,000	+71%	+$16.9K	﹤0.01%	245
2024 Q3	$29.1K	Hold	32,177	–	–	﹤0.01%	247
2024 Q2	$32.1K	Hold	32,177	–	–	0.01%	233
2024 Q1	$47.6K	Sell	32,177 -8,754	-21%	-$9.93K	0.01%	204
2023 Q4	$44.6K	Sell	40,931 -43,000	-51%	-$47.1K	0.01%	199
2023 Q3	$99K	Hold	83,931	–	–	0.02%	191
2023 Q2	$118K	Buy	83,931 +10,000	+14%	+$13.8K	0.03%	197
2023 Q1	$111K	Sell	73,931 -10,000	-12%	-$14K	0.03%	189
2022 Q4	$98.2K	Hold	83,931	–	–	0.03%	179
2022 Q3	$95K	Buy	83,931 +5,000	+6%	+$7.34K	0.03%	178
2022 Q2	$125K	Buy	78,931 +3,000	+4%	+$3.96K	0.04%	173
2022 Q1	$117K	Buy	75,931 +23,000	+43%	+$35.7K	0.03%	179
2021 Q4	$130K	Buy	52,931 +5,000	+10%	+$11.7K	0.04%	186
2021 Q3	$121K	Hold	47,931	–	–	0.04%	183
2021 Q2	$137K	Buy	47,931 +3,000	+7%	+$7.76K	0.05%	174
2021 Q1	$106K	Buy	+44,931	New	+$108K	0.04%	158

Other funds holding LCTX